Assessing the value of treatments to increase height

New England Journal of Medicine

Volumn 364, Issue 13, 2011, Pages 1274-1276

  Cuttler, Leona ^a,b   Rosenfield, Robert L ^c  

^a Cleveland Clinic Endocrinology and Metabolism Institute   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GROWTH HORMONE; PLACEBO;

BODY HEIGHT; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG POTENTIATION; EDITORIAL; GROWTH DISORDER; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; TURNER SYNDROME; VELOCITY;

EID: 79953231177     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1012987     Document Type: Editorial

References (13)

1. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med 2011;364:1230-42.
2. Tauer CA. The NIH trials of growth hormone for short stature. IRB 1994;16:1-9.
3. Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW. Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005;90:6424-30. (Pubitemid 41759295)
4. Stephure DK. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360-6. (Pubitemid 41014298)
5. Davenport ML, Crowe BJ, Travers SH, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406-16. (Pubitemid 47435312)
6. Carel JC, Ecosse E, Bastie-Sigeac I, et al. Quality of life determinants in young women with Turner's syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab 2005;90:1992-7. (Pubitemid 40586230)
7. Bryant J, Cave C, Mihaylova B, et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-168.
8. Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-209.
9. Pitukcheewanont P, Numbenjapon N, Safani D, Rossmiller S, Gilsanz V, Costin G. Bone size and density measurements in prepubertal children with Turner syndrome prior to growth hormone therapy. Osteoporos Int 2010 September 9 (Epub ahead of print).
10. Butler LM, Potischman NA, Newman B, et al. Menstrual risk factors and early-onset breast cancer. Cancer Causes Control 2000;11:451-8. (Pubitemid 30345242)
11. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
12. Hsieh RW, Rajan SS, Sharma SK, Greene GL. Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids 2008;73:59-68. (Pubitemid 350236293)
13. Silvers JB, Marinova D, Mercer MB, Connors A, Cuttler L. A national study of physician recommendations to initiate and discontinue growth hormone for short stature. Pediatrics 2010;126:468-76.